Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25603694 | 0.97 | HSD11B1 (0.33) | MAPTHSD11B1 | |
| SCHEMBL25844095 | 0.94 | MAPT (0.34) | NPC1RAB9AMAPTKDM4E | |
| SCHEMBL25603872 | 0.94 | PIK3CA (0.33) | NPC1RAB9AMAPTTP53KDM4E | |
| SCHEMBL3147166 | 0.94 | NPC1 (0.33) | NPC1RAB9AMAPTTP53KDM4E | |
| SCHEMBL3141410 | 0.94 | NPC1 (0.33) | NPC1RAB9AMAPTTP53KDM4E | |
| SCHEMBL3150887 | 0.93 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL4040445 | 0.93 | PGR (0.33) | NPC1RAB9AMAPTTP53KDM4E | |
| SCHEMBL25603169 | 0.93 | NPC1 (0.31) | NPC1RAB9A | |
| SCHEMBL4696184 | 0.93 | NPC1 (0.32) | NPC1RAB9AMAPTTP53KDM4E | |
| SCHEMBL25601409 | 0.93 | PDK2 (0.31) | NPC1RAB9AMAPTTP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8308995-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120138876-A1 | CHROMENE COMPOUND | KASAI SOKO (JP) | 2012-06-07 | — | — | US | disclosed |
| US-8147726-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20110062396-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120138876-A1 | CHROMENE COMPOUND | CHRM1, CBX8, CBX7 | NPC1 1130/4885RAB9A 1112/4885MAPT 3134/4885 |
| US-20110062396-A1 | CHROMENE COMPOUND | CDYL, NR0B1, NR1H2 | NPC1 809/4885RAB9A 841/4885MAPT 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.